In preclinical mouse studies, administration of AU-007 in combination with IL-2 induced effector T cell and NK cell proliferation in the absence of Treg expansion and showed anti-tumor efficacy in a B16F10 melanoma model (156). Here, IL2 is linked to melanoma.